

Regimen Monograph

[Regimen Name](#) | [Drug Regimen](#) | [Cycle Frequency](#) | [Premedication and Supportive Measures](#) | [Dose Modifications](#) | [Adverse Effects](#) | [Interactions](#) | [Drug Administration and Special Precautions](#) | [Recommended Clinical Monitoring](#) | [Administrative Information](#) | [References](#) | [Other Notes](#) | [Disclaimer](#)

A - Regimen Name

CETU Regimen

Cetuximab

Disease Site Head and Neck**Intent** Palliative**Regimen Category** **Evidence-Informed :**

Regimen is considered appropriate as part of the standard care of patients; meaningfully improves outcomes (survival, quality of life), tolerability or costs compared to alternatives (recommended by the Disease Site Team and national consensus body e.g. pan-Canadian Oncology Drug Review, pCODR). Recommendation is based on an appropriately conducted phase III clinical trial relevant to the Canadian context OR (where phase III trials are not feasible) an appropriately sized phase II trial. Regimens where one or more drugs are not approved by Health Canada for any indication will be identified under Rationale and Use.

Rationale and Uses For use as maintenance in patients with stable disease after CISPFU+CETU or CRBPFU+CETU[back to top](#)

B - Drug Regimen

cetuximab	250 mg /m ²	IV	Days 1, 8, 15
---------------------------	------------------------	----	---------------

(This drug is not currently publicly funded for this regimen and intent)

[back to top](#)

C - Cycle Frequency

REPEAT EVERY 21 DAYS

Until disease progression or unacceptable toxicity

[back to top](#)

D - Premedication and Supportive Measures

Antiemetic Regimen: Minimal

- Also refer to [CCO Antiemetic Recommendations](#).

Screen for hepatitis B virus in all cancer patients starting systemic treatment. Refer to the [hepatitis B virus screening and management](#) guideline.

Premedications (prophylaxis for infusion reaction):

- H1-receptor antagonist (e.g. diphenhydramine 50 mg IV) 30-60 minutes prior to the dose.
- Corticosteroid IV 30-60 minutes prior to the dose.
- Consider discontinuing pre-medications after the 2nd infusion based on clinical judgment and the presence/severity of IR.

Other Supportive Care:

- Patients should use sun protection while receiving cetuximab and for 2 months after treatment completion.
- Consider pre-emptive therapy for EGFR inhibitor-related skin toxicity; the following was shown to be of benefit with panitumumab treatment, starting the day before treatment and continued until week 6. (Lacouture et al, 2010):
 - ◊ Skin moisturizer applied to the face, hands, feet, neck, back and chest in the morning
 - ◊ Sunscreen to exposed areas (SPF \geq 15, UVA and UVB) before going outdoors
 - ◊ Hydrocortisone 1% cream to the face, hands, feet, neck, back and chest at bedtime
 - ◊ Doxycycline (or minocycline) PO
- Refer to the Canadian recommendations for the management of skin rash during EGFR-targeted monoclonal antibody treatment for GI malignancies. (Melosky et al, 2009)

[back to top](#)

E - Dose Modifications

Doses should be modified according to the protocol by which the patient is being treated.

Dosage with toxicity

Dose Level	Cetuximab Dose (mg/m² weekly)
0	250
-1	200
-2	150
-3	Discontinue

Toxicity	Action	Next cycle
Pneumonitis	Hold and investigate	Discontinue if confirmed.
Keratitis	Hold and refer to ophthalmologist	Consider discontinuation.

Dosage modification for skin toxicity:

Grade 3 or 4 Rash	Action	Outcome	Cetuximab Dose
1st occurrence	Delay infusion 1 to 2 weeks	Improvement	Resume at same dose
		No improvement	Discontinue
2nd occurrence	Delay infusion 1 to 2 weeks	Improvement	Resume at 1 dose level ↓
		No improvement	Discontinue
3rd occurrence	Delay infusion 1 to 2 weeks	Improvement	Resume at 1 dose level ↓
		No improvement	Discontinue
4th occurrence OR any occurrence of SJS/TENS	Discontinue		

Management of Infusion-related reactions:

Also refer to the CCO guideline for detailed description of [Management of Cancer Medication-Related Infusion Reactions](#).

Grade	Management	Re-challenge
1 or 2	<ul style="list-style-type: none"> • Stop or slow the infusion rate. • Manage the symptoms. <p>Restart:</p> <ul style="list-style-type: none"> • The infusion may be restarted at a slower rate (50% of the rate at which the IR occurred) once symptoms have resolved. 	<ul style="list-style-type: none"> • Re-challenge with a reduced infusion rate of 50% at which the infusion reaction occurred.
3 or 4	<ul style="list-style-type: none"> • Stop treatment. • Aggressively manage symptoms. <p>Restart:</p> <ul style="list-style-type: none"> • Once symptoms resolve, the infusion can be restarted at a slower rate, unless a serious reaction occurred (i.e., vital signs compromised; anaphylaxis). 	<ul style="list-style-type: none"> • Permanently discontinue (do not re-challenge).

Hepatic Impairment

Population pharmacokinetics suggest no significant impact.

Renal Impairment

Population pharmacokinetics suggest no significant impact.

[back to top](#)

F - Adverse Effects

Refer to [cetuximab](#) drug monograph(s) for additional details of adverse effects.

Very common (≥ 50%)	Common (25-49%)	Less common (10-24%)	Uncommon (< 10%), but may be severe or life- threatening
<ul style="list-style-type: none"> • Rash (may be severe) • Fatigue • Anorexia • Nausea, vomiting • Abdominal pain • Constipation 	<ul style="list-style-type: none"> • Neuropathy • Cough, dyspnea • Hypomagnesemia • Infection (may be severe) • Diarrhea • Headache • Mucositis • Insomnia • Nail disorder 	<ul style="list-style-type: none"> • Flu-like symptoms • Infusion-related reaction (may be severe) • Mood changes, Confusion • Musculoskeletal pain • Dry mouth • Increased LFTs • Dizziness • Dysgeusia 	<ul style="list-style-type: none"> • Hemorrhage • Arterial/venous thromboembolism • Arrhythmia • GI obstruction/perforation • Pancreatitis • Pneumonitis • Keratitis • Nephrotoxicity • Stevens-Johnson syndrome • Toxic epidermal necrolysis • Sudden death

[back to top](#)

G - Interactions

Refer to [cetuximab](#) drug monograph(s) for additional details.

[back to top](#)

H - Drug Administration and Special Precautions

Refer to [cetuximab](#) drug monograph(s) for additional details.

Administration:

- Do not shake or further dilute the solution.
- DO NOT administer as an IV push or bolus.
- Transfer undiluted solution into a compatible empty infusion container.
- Cetuximab is compatible with:
 - glass,
 - polyolefin, polyethylene, ethylene vinyl acetate (EVA), DEHP plasticized PVC, or PVC bags,
 - polyethylene, EVA, PVC, polybutadiene or polymethane infusion sets, and
 - polyethersulfone, polyamide or polysulfone in-line filters.
- Administer the undiluted solution via a low protein binding 0.22-micrometer in-line filter, piggybacking to the patient's infusion line.
- Infuse initial loading dose over 2 hours, and maintenance dose over 1 hour (maximum rate 10 mg/min). (May require infusion at slower rate in those who experienced infusion reactions).
- Prime administration line with drug solution before infusion. May use NS to flush line at the end of infusion.
- A 1-hour observation period is recommended following each cetuximab infusion. Longer observation periods may be required in those who experienced infusion reactions.
- Should not be mixed or diluted with other drugs.
- Store unopened vials at 2-8°C.

Also refer to the CCO guideline for detailed description of [Management of Cancer Medication-Related Infusion Reactions](#).

Contraindications:

- Patients with known hypersensitivity to this drug or any of its components

Other Warnings/Precautions:

- Patients with a history of, or pre-existing keratitis, dry eyes or contact lens use
- Patients with poor performance status, or cardiopulmonary disease are at increased risk of severe hypersensitivity

Pregnancy/Lactation:

- This regimen is not recommended for use in pregnancy. Adequate contraception should be used by patients and their partners while on treatment and after the last treatment dose. Recommended methods and duration of contraception may differ depending on the treatment. Refer to the drug monograph(s) for more information.
- Breastfeeding is not recommended during treatment and after the last treatment dose. Refer to the drug monograph(s) for recommendations after the last treatment dose (if available).
- Fertility effects: Unknown

[back to top](#)

I - Recommended Clinical Monitoring

Treating physicians may decide to monitor more or less frequently for individual patients but should always consider recommendations from the product monograph.

Refer to the [hepatitis B virus screening and management](#) guideline for monitoring during and after treatment.

Recommended Clinical Monitoring

- Electrolytes, including serum magnesium, potassium and calcium; Baseline, weekly, and monthly for 2 months following completion of therapy
- CBC; Baseline and as clinically indicated
- Renal function; Baseline and as clinically indicated
- Clinical toxicity assessment for infusion reactions, skin, nail, cardiac, thromboembolism, GI, hypersensitivity, respiratory symptoms, fatigue and keratitis; at each visit
- Grade toxicity using the current [NCI-CTCAE \(Common Terminology Criteria for Adverse Events\) version](#)

[back to top](#)

J - Administrative Information

Approximate Patient Visit	First cycle; 2.5 hours; Subsequent cycles: 1.5 hours
Pharmacy Workload (average time per visit)	24.85 minutes
Nursing Workload (average time per visit)	55.595 minutes

[back to top](#)

K - References

Cetuximab drug monograph, Ontario Health (Cancer Care Ontario).

Lacouture, ME, Mitchell EP, Piperdi B et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. *J Clin Oncol* 2010; 28: 1351-7.

Matuschek C , Bölke E, Belka C, et al. Feasibility of 6 month maintenance cetuximab after adjuvant concurrent chemoradiation plus cetuximab in squamous cell carcinoma of the head and neck. *Strahlenther Onkol* 2013;189(8):62531.

Melosky B, Burkes R, Rayson D, et al. Management of skin rash during EGFR-targeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations. *Current Oncology* 2009; 16(10): 14-24.

July 2023 Expanded into full regimen monograph

[back to top](#)

M - Disclaimer

Regimen Abstracts

A Regimen Abstract is an abbreviated version of a Regimen Monograph and contains only top level information on usage, dosing, schedule, cycle length and special notes (if available). It is intended for healthcare providers and is to be used for informational purposes only. It is not intended to constitute or be a substitute for medical advice, and all uses of the Regimen Abstract are subject to clinical judgment. Such information is provided on an "as-is" basis, without any representation, warranty, or condition, whether express, or implied, statutory or otherwise, as to the information's quality, accuracy, currency, completeness, or reliability, and Cancer Care Ontario disclaims all liability for

the use of this information, and for any claims, actions, demands or suits that arise from such use.

Information in regimen abstracts is accurate to the extent of the ST-QBP regimen master listings, and has not undergone the full review process of a regimen monograph. Full regimen monographs will be published for each ST-QBP regimen as they are developed.

Regimen Monographs

Refer to the [New Drug Funding Program](#) or [Ontario Public Drug Programs](#) websites for the most up-to-date public funding information.

The information set out in the drug monographs, regimen monographs, appendices and symptom management information (for health professionals) contained in the Drug Formulary (the "Formulary") is intended for healthcare providers and is to be used for informational purposes only. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects of a particular drug, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for a given condition. The information in the Formulary is not intended to constitute or be a substitute for medical advice and should not be relied upon in any such regard. All uses of the Formulary are subject to clinical judgment and actual prescribing patterns may not follow the information provided in the Formulary.

The format and content of the drug monographs, regimen monographs, appendices and symptom management information contained in the Formulary will change as they are reviewed and revised on a periodic basis. The date of last revision will be visible on each page of the monograph and regimen. Since standards of usage are constantly evolving, it is advised that the Formulary not be used as the sole source of information. It is strongly recommended that original references or product monograph be consulted prior to using a chemotherapy regimen for the first time.

Some Formulary documents, such as the medication information sheets, regimen information sheets and symptom management information (for patients), are intended for patients. Patients should always consult with their healthcare provider if they have questions regarding any information set out in the Formulary documents.

While care has been taken in the preparation of the information contained in the Formulary, such information is provided on an "as-is" basis, without any representation, warranty, or condition, whether express, or implied, statutory or otherwise, as to the information's quality, accuracy, currency, completeness, or reliability.

CCO and the Formulary's content providers shall have no liability, whether direct, indirect, consequential, contingent, special, or incidental, related to or arising from the information in the Formulary or its use thereof, whether based on breach of contract or tort (including negligence), and even if advised of the possibility thereof. Anyone using the information in the Formulary does so at his or her own risk, and by using such information, agrees to indemnify CCO and its content providers from any and all liability, loss, damages, costs and expenses (including legal fees and expenses) arising from such person's use of the information in the Formulary.

[back to top](#)